Loading
A phase 1/2 trial of CFI-402257 run by Canadian Cancer Trials Group, active and no longer recruiting.
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer is a phase 1/2 interventional study registered as NCT03568422 by Canadian Cancer Trials Group, with 37 participants planned, started 2019-02-05. Conditions recorded: Breast Cancer. Interventions recorded: CFI-402257 and Paclitaxel.
Shares CFI-402257, Treadwell Therapeutics, Breast cancer (all types) and the tag pipeline.
Shares CFI-402257, Treadwell Therapeutics and the tag pipeline.
Shares Treadwell Therapeutics, Breast cancer (all types) and the tag pipeline.
Shares Treadwell Therapeutics, Breast cancer (all types) and the tag pipeline.
Shares Treadwell Therapeutics and the tag pipeline.
Shares Treadwell Therapeutics and the tag pipeline.
Shares CFI-402257, Breast cancer (all types) and the tag pipeline.
Shares Treadwell Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/